(Q34050684)

30 July 2017

1 reference

title

Inhibitors of HIV-1 reverse transcriptase. (English)

1 reference

30 July 2017

Parniak MA

1

1 reference

30 July 2017

Sluis-Cremer N

series ordinal

2

1 reference

30 July 2017

publication date

1 January 2000

1 reference

30 July 2017

published in

Advances in Pharmacology

1 reference

30 July 2017

volume

49

1 reference

30 July 2017

page(s)

67-109

1 reference

HIV resistance to zidovudine: the role of pyrophosphorolysis

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Luminescent immobilized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5'-triphosphate sulfurylase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Combination therapy with zidovudine, didanosine and saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Synergistic inhibition of HIV-1 reverse transcriptase DNA polymerase activity and virus replication in vitro by combinations of carboxanilide nonnucleoside compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Combination therapy for HIV-1 infection-overview: preclinical and clinical analysis of antiretroviral combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Crystal structures of the Klenow fragment of Thermus aquaticus DNA polymerase I complexed with deoxyribonucleoside triphosphates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Combination therapy in primary HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

High resolution structures of HIV-1 RT from four RT-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Development of nonnucleoside HIV reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-nucleotide incorporation assay

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2800%2949024-1

7 January 2021

10.1016/S1054-3589(00)49024-1

Identifiers

DOI

1 reference

30 July 2017

1 reference